医药深度复盘+最新观点 春节期间，医药重要事件梳理 20260223 中国创新药对外授权 BD 交易活跃，截至 2 月 15 日，总首付款金额已达 30 亿美元，总体量 490 亿美元，远超 2025 年同期水平，预示 2026 年 BD 交易将大幅跃升。石药集团与阿斯利康合作金额高达 185 亿美元， 为近年来新高。 中国药企海外研发取得进展，如石药集团 PCSK9 小核酸新药 SYH2053 启动三期试验，科伦博泰卢康沙妥珠单抗启动全球临床试验，翰森制药 阿美替尼获欧盟批准，石药集团长效 GLP1/GIP 双抗 SYH2,082 获 FDA 批准 IND。 医改政策方面，《基要目录管理办法》修订强调与集采、医保衔接，原 则上每三年调整一次，集采纳入基要目录节奏或加快。已完成的集采政 策导向更温和，注重质量和反内卷，中选率达 93%，对市场结构影响较 小。 药品集采续约注重临床需求匹配度和投标供应商质量，覆盖率达 98%， 调整较小，趋向理性。续约采用询价方式，控制价格风险，符合反内卷 导向。前沿生物与 GSK 达成小核酸 BD 合作，首付款 4,000 万美元，里 程碑付款 9.63 亿美元，验证了早期研 ...

4、美称中国一人工智能企业违反美出口管制，外交部：中方已多次表明原则立场 1、特朗普考虑征收新的国家安全关税 美国最高法院上周的一项裁决宣布总统特朗普第二任期的多项征税无效，现在特朗普政府考虑对六 个行业征收新的国家安全关税。据知情人士透露，考虑征收的新关税可能涵盖大型电池、铸铁和铁配 件、塑料管道、工业化学品以及电网和电信设备等行业。这些关税将根据《1962年贸易扩展法》(Trade Expansion Act of 1962)第232条征收，该条款赋予总统基于国家安全风险征收关税的广泛权力。新的第 232条关税将独立于特朗普自最高法院周五上午驳回其多项关税以来已宣布的其他税项。已宣布的关税 包括一项新的15%关税，可维持五个月，以及计划在该期限后征收的多项关税，后者将根据《贸易法》 (Trade Act)第301条发布。 2、美媒：特朗普军方最高顾问警告袭击伊朗风险 据Axios援引两名消息人士透露，美军参谋长联席会议主席丹・凯恩将军已向特朗普总统及高级官 员建议，对伊朗发动军事行动可能存在重大风险，尤其是可能陷入长期冲突。 特朗普政府高层正就是 如何应对伊朗对峙、以及不同方案将带来何种后果展开激烈争论。 ...

北水恢复交易首日，港股三大指数集体走低，恒指再度失守两万七大关，恒科指数则跌超2%。截至收 盘，恒生指数跌1.82%或491.59点，报26590.32点，全日成交额2509.92亿港元；恒生国企指数跌2.06%， 报9007.86点；恒生科技指数跌2.13%，报5270.70点。 银河证券认为，科技板块仍是中长期投资主线，经历近期的回调后，估值压力下降，在AI大模型更新 加快、AI应用加速推进的背景下，相关板块有望反弹回升。此外，中东地缘风险升温、美国关税政策 调整推升避险情绪，贵金属、能源板块有望震荡上行；消费板块当前估值偏低，随着促消费政策加码， 消费活力逐步释放，板块仍具上涨空间。 蓝筹股表现 万洲国际(00288)领涨蓝筹。截至收盘，涨4.42%，报10.39港元，成交额3.26亿港元，贡献恒指5.87点。 瑞银发布研报称，展望未来，该行相信万洲国际正进入盈利波动性较低的阶段，受惠于美国生猪价格前 景更趋稳定，以及业务策略转向利润较高的包装肉制品，将提升盈利及股东回报的能见度。 其他蓝筹股方面，恒基地产(00012)涨2.08%，报35.32港元，贡献恒指1.69点；华润啤酒(00291)涨 2.0 ...

Market Overview - On the first trading day after the resumption of Northbound trading, Hong Kong's three major indices collectively declined, with the Hang Seng Index falling below the 27,000 mark, closing down 1.82% or 491.59 points at 26,590.32 points, with a total turnover of HKD 250.99 billion [1] - The Hang Seng China Enterprises Index dropped 2.06% to 9,007.86 points, while the Hang Seng Tech Index fell 2.13% to 5,270.70 points [1] Sector Performance - The technology sector remains a long-term investment focus, with valuation pressure easing after recent pullbacks, and potential for rebound driven by accelerated AI model updates and applications [1] - The energy and precious metals sectors are expected to rise amid heightened geopolitical risks in the Middle East and adjustments in U.S. tariff policies [1] - The consumer sector, currently undervalued, is anticipated to have upward potential as consumption policies are strengthened [1] Blue-Chip Stocks - WH Group (00288) led blue-chip gains, rising 4.42% to HKD 10.39, contributing 5.87 points to the Hang Seng Index [2] - Other notable blue-chip performers included Henderson Land (00012) up 2.08% and China Resources Beer (00291) up 2.02% [2] - China Biologic Products (01177) fell 6.58%, negatively impacting the index by 7.48 points [2] Hot Sectors - Major tech stocks faced pressure, with Tencent down over 3% and Alibaba down over 2% [3] - Storage concepts saw significant gains, with Zhaoyi Innovation (03986) up 11.91% and Longsys Technology (06809) up 4.92% [3] - Oil and gas stocks rose amid concerns over escalating tensions in Iran, with Shandong Molong (00568) up 11.41% [4] AI and Technology - The AI sector continues to show promise, with significant growth in token usage, particularly in Chinese models, which account for 61% of the total token volume [5] - The market anticipates ongoing rapid growth in AI applications and commercial viability [5] Film Sector - The film sector faced challenges, with the 2026 Spring Festival box office down approximately 40% year-on-year, indicating a need for improved content quality [6] - Major film stocks like Maoyan Entertainment (01896) and Huayi Brothers (01003) saw declines of 8.18% and 5.26%, respectively [6] Notable Stock Movements - Kwan Hung Holdings (01888) surged 12.37% following a profit forecast indicating a 165% increase in net profit for the fiscal year ending December 2025 [7] - Weichai Power (02338) rose 7.29% after a report highlighted its emergency generator's use in a major data center [8] - China Shipbuilding Defense (00317) reached a new high, up 5.37%, following a significant shipbuilding contract announcement [9] - Standard Chartered (02888) saw a 3.07% increase after reporting a 6% rise in operating income for the fiscal year 2025 [10] - China Duty Free Group (01880) faced a 10.51% drop due to losing some operating rights at major airports [11]

凤凰网财经讯 港股2月24日收盘走低，恒生指数收报26590.32点，跌491.59点，跌幅1.82%；恒生科技指 数收报5270.7点，跌114.65点，跌幅2.13%。 恒生指数成分股中万洲国际、恒基地产、华润啤酒涨幅居前，中国生物制药、翰森制药、中国人寿跌幅 靠前。恒生科技指数成分股中华虹半导体、联想集团、小鹏汽车-W涨幅居前，金蝶国际、商汤-W、腾 讯音乐-SW跌幅靠前。 ...

腾讯音乐-SW跌5.702%，商汤-W跌5.776%，泡泡玛特跌6.039%，中国人寿跌6.073%，中国生物制药跌 6.579%，翰森制药跌6.703%，金蝶国际跌7.956%。 来源：滚动播报 ...

截至11:07，港股通创新药ETF(159570)标的指数热门股多数回调：石药集团、中国生物制药、三生制药、翰森制药、荣昌生物跌超5%，信达生物跌超4%， 康方生物跌超3%。 | 序号 | 代码 | 名称 | 估算板車 | 涨跌幅 | 17.47 80 ▼ | | --- | --- | --- | --- | --- | --- | | 1 | 1801 | 信达生物 | 10.51% | -0.56% | 6.81亿 | | 2 | 1093 | 石药集团 | 12.18% | -3.15% | 5.98 7. | | 3 | 6160 | 高密被田 | 10.99% | -1.13% | 2.83 Z | | 4 | 1530 | 三生制药 | 6.50% | -2.57% | 2.65 Z | | 5 | 9926 | 康方生物 | 8.49% | -1.33% | 2.57 Z | | 6 | 3692 | 翰森制药 | 6.84% | -1.84% | 1.99 Z | | 7 | 1177 | 中国生物制药 | 10.01% | -3.66% | 1.74Z | | 8 | 6990 | 科伦博 ...

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **Pharmaceutical (Pharma)** and **Biopharmaceutical/Biotech** sectors, highlighting companies with potential for value re-evaluation and those entering a performance ramp-up phase [1][2]. Core Insights and Arguments 1. **Value Re-evaluation of Pharma Companies**: - There is a recommendation to further support Pharma companies that have the potential for value re-evaluation, particularly emphasizing key marginal changes. The BD (Business Development) revenue for Pharma is expected to normalize, which will drive an upward shift in the valuation framework [1][2]. 2. **Performance Ramp-up in Biopharma/Biotech**: - Continuous recommendation for Biopharma/Biotech companies that are entering a performance ramp-up phase and have pipelines that are consistently delivering results. The expectation is that by 2026, leading Biopharma/Biotech companies will enter a period of accelerated performance [2]. 3. **Key Marginal Changes**: - The core marginal change driving the value re-evaluation logic for Pharma companies is the normalization of BD revenue. This is supported by two main factors: - Leading Pharma companies have a more comprehensive technology platform and pipeline layout, enhancing their ability to continuously produce BD assets [2]. - External transactions are evolving from sporadic single-asset licensing to a more platform-based and series-based licensing model, making upfront payments, milestones, and revenue sharing more replicable and predictable. Recent collaborations, such as the partnership between **Shiyao** and **AstraZeneca** for a long-acting weight loss drug (total package of $18.5 billion) and **Innovent** with **Eli Lilly** in oncology and immunology (total package of $8.9 billion), exemplify this trend [2]. Recommendations - Specific companies recommended for investment include: - **Hengrui Medicine** - **Hansoh Pharmaceutical** - **Shiyao Group** (new addition in February) - **China National Pharmaceutical Group** - **Sinopharm** (new addition in February) - **Haisco** [2]. Additional Important Insights - The oncology, metabolism, and autoimmune sectors are expected to see a concentration of critical data releases. The integration of new technology platforms such as small nucleic acids, bispecific/trispecific antibodies, next-generation ADCs, and PROTAC/molecular glue is anticipated to provide significant valuation elasticity for leading companies at key data points, potentially opening up overseas BD opportunities [3].

【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治疗； 石药集团： 1）2/16 公司公告旗下受体偏向性GLP1/GIP激动剂月制剂SYH2082在美国获批临床； 信立泰： 翰森制药： 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治 【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 翰森制药： 1）2/20 公司在《欧洲呼吸杂志子刊-开放研究》ERJ OPEN RESEARCH上披露了IL17RB单抗SM17针对CRSWNP和 IPF ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 个股表现上，恒基地产、万州国际、中国石油股份领涨恒指成分股；泡泡玛特、瀚森制药、阿里健康领 跌恒指成分股。万州国际盘中还创出历史新高。 恒生科技指数表现更弱，开盘报5330.26点，下跌1.02%，盘中持续走低，截至9时38分，报5255.02点， 跌幅扩大至2.42%。 板块表现上，大多数板块下跌，其中信息科技、软件服务板块领跌；石油天然气板块逆势上涨。 今日（2月24日），港股开盘后呈现震荡走弱态势，受隔夜美股大幅回调拖累，主要股指集体低开，随 后持续下探，市场呈现结构性分化格局。截至9时38分，恒生指数与恒生科技指数均出现明显下跌，部 分板块逆势异动，个股表现分化显著。 指数方面，恒生指数开盘报26913.68点，下跌0.62%，随后震荡下行，截至9时38分，报26682.85点，跌 幅扩大至1.47%。 ...